Paper35548360
Engineering of Stimulus-Responsive Pirfenidone Liposomes for Pulmonary Delivery During Treatment of Idiopathic Pulmonary Fibrosis.
Han M and 9 others. Front Pharmacol, 2022. Cited by 22 papers, by iCite.
Cite this record
ConductScience Library. Engineering of Stimulus-Responsive Pirfenidone Liposomes for Pulmonary Delivery During Treatment of Idiopathic Pulmonary Fibrosis. Papers, record 35548360. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/35548360
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Engineering of Stimulus-Responsive Pirfenidone Liposomes for Pulmonary Delivery During Treatment of Idiopathic Pulmonary Fibrosis.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References32
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 33076918 | Novel drug delivery systems targeting oxidative stress in chronic obstructive pulmonary disease: a review. | J Nanobiotechnology | 2020 | https://conductscience.org/library/papers/33076918 | PubMed |
| 2 | 30742982 | Afatinib-loaded immunoliposomes functionalized with cetuximab: A novel strategy targeting the epidermal growth factor receptor for treatment of non-small-cell lung cancer. | Int J Pharm | 2019 | https://conductscience.org/library/papers/30742982 | PubMed |
| 3 | 17244708 | Rapid transport of large polymeric nanoparticles in fresh undiluted human mucus. | Proc Natl Acad Sci U S A | 2007 | https://conductscience.org/library/papers/17244708 | PubMed |
| 4 | 23372951 | A review of current and novel therapies for idiopathic pulmonary fibrosis. | J Thorac Dis | 2013 | https://conductscience.org/library/papers/23372951 | PubMed |
| 5 | 24535066 | Bronchoalveolar pH and inflammatory biomarkers in newly diagnosed IPF and GERD patients: a case-control study. | Med Sci Monit | 2014 | https://conductscience.org/library/papers/24535066 | PubMed |
| 6 | 28696894 | Preference of Aerosolized Pirfenidone to Oral Intake: An Experimental Model of Pulmonary Fibrosis by Paraquat. | J Aerosol Med Pulm Drug Deliv | 2018 | https://conductscience.org/library/papers/28696894 | PubMed |
| 7 | 21471066 | An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. | Am J Respir Crit Care Med | 2011 | https://conductscience.org/library/papers/21471066 | PubMed |
| 8 | 15947432 | Microcolony formation: a novel biofilm model of Pseudomonas aeruginosa for the cystic fibrosis lung. | J Med Microbiol | 2005 | https://conductscience.org/library/papers/15947432 | PubMed |
| 9 | 26902722 | Enhanced pulmonary delivery of fluticasone propionate in rodents by mucus-penetrating nanoparticles. | Int J Pharm | 2016 | https://conductscience.org/library/papers/26902722 | PubMed |
| 10 | 32575019 | Pirfenidone: A novel hypothetical treatment for COVID-19. | Med Hypotheses | 2020 | https://conductscience.org/library/papers/32575019 | PubMed |
| 11 | 31935633 | Low-level laser therapy attenuates lung inflammation and airway remodeling in a murine model of idiopathic pulmonary fibrosis: Relevance to cytokines secretion from lung structural cells. | J Photochem Photobiol B | 2020 | https://conductscience.org/library/papers/31935633 | PubMed |
| 12 | 21632796 | Antifibrotic activities of pirfenidone in animal models. | Eur Respir Rev | 2011 | https://conductscience.org/library/papers/21632796 | PubMed |
| 13 | 28091615 | Pirfenidone controls the feedback loop of the AT1R/p38 MAPK/renin-angiotensin system axis by regulating liver X receptor-α in myocardial infarction-induced cardiac fibrosis. | Sci Rep | 2017 | https://conductscience.org/library/papers/28091615 | PubMed |
| 14 | 29327616 | Nintedanib for the treatment of idiopathic pulmonary fibrosis. | Expert Opin Pharmacother | 2018 | https://conductscience.org/library/papers/29327616 | PubMed |
| 15 | 29313004 | Nanoparticles in the clinic. | Bioeng Transl Med | 2016 | https://conductscience.org/library/papers/29313004 | PubMed |
| 16 | 27005406 | Pirfenidone-induced severe phototoxic reaction in a patient with idiopathic lung fibrosis. | J Eur Acad Dermatol Venereol | 2016 | https://conductscience.org/library/papers/27005406 | PubMed |
| 17 | 11673205 | Predicting survival in idiopathic pulmonary fibrosis: scoring system and survival model. | Am J Respir Crit Care Med | 2001 | https://conductscience.org/library/papers/11673205 | PubMed |
| 18 | 32703779 | Pirfenidone plus inhaled N-acetylcysteine for idiopathic pulmonary fibrosis: a randomised trial. | Eur Respir J | 2021 | https://conductscience.org/library/papers/32703779 | PubMed |
| 19 | 16146340 | Carrier-based strategies for targeting protein and peptide drugs to the lungs. | AAPS J | 2005 | https://conductscience.org/library/papers/16146340 | PubMed |
| 20 | 26779535 | Pharmacological Treatment of Idiopathic Pulmonary Fibrosis: Current Approaches, Unsolved Issues, and Future Perspectives. | Biomed Res Int | 2015 | https://conductscience.org/library/papers/26779535 | PubMed |
Cited by8
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 22 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42688889 | Molecular insights of a Unani formulation in targeting fibrosis-associated diseases. | Front Pharmacol | 2026 | https://conductscience.org/library/papers/42688889 | PubMed |
| 41361355 | Network pharmacology and in vitro studies demonstrate modulation of fibrotic pathways by Swertia chirayita in pulmonary fibrosis. | Sci Rep | 2025 | https://conductscience.org/library/papers/41361355 | PubMed |
| 41010139 | Recent Advances in pH-Responsive Liposomes: Lessons Learnt and New Directions in Nanomedicine Development. | Materials (Basel) | 2025 | https://conductscience.org/library/papers/41010139 | PubMed |
| 40241794 | SIRT3/6/7: promising therapeutic targets for pulmonary fibrosis. | Front Cell Dev Biol | 2025 | https://conductscience.org/library/papers/40241794 | PubMed |
| 39918485 | Citrus pectin-coated inhalable PLGA nanoparticles for treatment of pulmonary fibrosis. | J Mater Chem B | 2025 | https://conductscience.org/library/papers/39918485 | PubMed |
| 38065244 | Emerging delivery approaches for targeted pulmonary fibrosis treatment. | Adv Drug Deliv Rev | 2024 | https://conductscience.org/library/papers/38065244 | PubMed |
| 37608885 | Progress in understanding and treating idiopathic pulmonary fibrosis: recent insights and emerging therapies. | Front Pharmacol | 2023 | https://conductscience.org/library/papers/37608885 | PubMed |
| 36998607 | Arctiin-encapsulated DSPE-PEG bubble-like nanoparticles inhibit alveolar epithelial type 2 cell senescence to alleviate pulmonary fibrosis via the p38/p53/p21 pathway. | Front Pharmacol | 2023 | https://conductscience.org/library/papers/36998607 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/35548360
GET https://conductscience.org/api/papers/v1/35548360/references?page=2